CCM2 Protein

Migration, Crosslink

📖

CCM2 Protein

active

wiki page Created: 2026-04-02T07:19:08 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-proteins-ccm2-protein

📖 Wiki Page

protein1978 wordssynced 2026-04-02

CCM2 Protein

<div class="infobox infobox-protein">
<table>
<tr><th>Protein Name</th><td><strong>CCM2</strong></td></tr> [@fischer2013]
<tr><th>Full Name</th><td>CCM2 scaffold protein (Malcavernin)</td></tr> [@zhou2016]
<tr><th>Gene Symbol</th><td><a href="/genes/ccm2">CCM2</a></td></tr> [@castro2009]
<tr><th>UniProt ID</th><td><a href="https://www.uniprot.org/uniprot/Q9BSQ5">Q9BSQ5</a></td></tr> [@wang2018]
<tr><th>Protein Family</th><td>CCM family</td></tr>
<tr><th>Molecular Weight</th><td>~52 kDa</td></tr> [@snellings2021]
<tr><th>Length</th><td>444 amino acids</td></tr>
<tr><th>Subcellular Location</th><td>Cytoplasm, cell junctions</td></tr>
<tr><th>Brain Expression</th><td>Endothelial cells, [neurons](/entities/neurons)</td></tr>
<tr><th>Associated Diseases</th><td>Cerebral cavernous malformation (CCM), hemorrhage</td></tr>
</table>
</div>

Overview

CCM2 (Cerebral Cavernous Malformation 2 protein), also known as malcavernin, is a critical scaffold protein encoded by the CCM2 gene located on chromosome 7p15-p13 [@craig2005]. This protein plays an essential role in vascular development, endothelial function, and the maintenance of [blood-brain barrier](/entities/blood-brain-barrier) (BBB) integrity [@faurobert2010]. CCM2 is a member of the CCM protein family, which includes CCM1 (KRIT1) and CCM3 (PDCD10), and these proteins work together to form a ternary complex that regulates multiple signaling pathways critical for vascular homeostasis [@hilder2007].

...

CCM2 Protein

<div class="infobox infobox-protein">
<table>
<tr><th>Protein Name</th><td><strong>CCM2</strong></td></tr> [@fischer2013]
<tr><th>Full Name</th><td>CCM2 scaffold protein (Malcavernin)</td></tr> [@zhou2016]
<tr><th>Gene Symbol</th><td><a href="/genes/ccm2">CCM2</a></td></tr> [@castro2009]
<tr><th>UniProt ID</th><td><a href="https://www.uniprot.org/uniprot/Q9BSQ5">Q9BSQ5</a></td></tr> [@wang2018]
<tr><th>Protein Family</th><td>CCM family</td></tr>
<tr><th>Molecular Weight</th><td>~52 kDa</td></tr> [@snellings2021]
<tr><th>Length</th><td>444 amino acids</td></tr>
<tr><th>Subcellular Location</th><td>Cytoplasm, cell junctions</td></tr>
<tr><th>Brain Expression</th><td>Endothelial cells, [neurons](/entities/neurons)</td></tr>
<tr><th>Associated Diseases</th><td>Cerebral cavernous malformation (CCM), hemorrhage</td></tr>
</table>
</div>

Overview

CCM2 (Cerebral Cavernous Malformation 2 protein), also known as malcavernin, is a critical scaffold protein encoded by the CCM2 gene located on chromosome 7p15-p13 [@craig2005]. This protein plays an essential role in vascular development, endothelial function, and the maintenance of [blood-brain barrier](/entities/blood-brain-barrier) (BBB) integrity [@faurobert2010]. CCM2 is a member of the CCM protein family, which includes CCM1 (KRIT1) and CCM3 (PDCD10), and these proteins work together to form a ternary complex that regulates multiple signaling pathways critical for vascular homeostasis [@hilder2007].

The CCM2 protein is expressed predominantly in endothelial cells throughout the vascular system, with particularly high expression in the brain's microvasculature [@guzeloglukayisli2012]. Its dysfunction has been directly linked to the pathogenesis of cerebral cavernous malformations (CCMs), which are vascular malformations characterized by closely packed, thin-walled capillary cavities that can cause seizures, hemorrhagic stroke, and neurological deficits [@morrison2023].

Protein Structure and Biochemistry

Domain Architecture

CCM2 possesses a distinctive domain architecture that enables its function as a molecular scaffold:

N-terminal Phosphotyrosine-Binding (PTB) Domain: The PTB domain (residues 1-200) is responsible for binding to phosphorylated tyrosine residues on target proteins, particularly the cytoplasmic domain of KRIT1/CCM1 [@zawistowski2005]. This domain adopts a classical PTB fold that recognizes NPXY motifs in client proteins.
C-terminal Coiled-Coil Domain: The coiled-coil domain (residues 300-444) mediates homotypic and heterotypic protein-protein interactions, allowing CCM2 to form complexes with CCM1 and CCM3 [@voss2007]. This domain is critical for the trimeric complex formation essential for CCM protein function.
Proline-Rich Regions: Interspersed proline-rich sequences (residues 200-300) serve as binding sites for SH3 domain-containing proteins, including components of the actin cytoskeleton signaling machinery [@zhang2013].

Post-Translational Modifications

CCM2 undergoes several post-translational modifications that regulate its activity:

Phosphorylation: CCM2 can be phosphorylated at tyrosine residues, which modulates its interaction with binding partners [@uhlik2005]. The PTB domain recognizes these phosphorylated forms.
Ubiquitination: CCM2 is subject to ubiquitination, which targets it for degradation via the proteasome pathway [@liu2018]. This modification provides a mechanism for regulating protein turnover.
Sumoylation: SUMOylation of CCM2 has been reported and may affect its subcellular localization and protein interactions [@glineur2019].

Biological Functions

Vascular Development and Maintenance

CCM2 plays a fundamental role in cardiovascular development and vascular maintenance:

Angiogenesis Regulation: CCM2 regulates endothelial cell proliferation, migration, and tube formation during angiogenesis [@whitehead2009]. The CCM complex negatively regulates vascular endothelial growth factor (VEGF) signaling to prevent excessive vessel formation.

Endothelial Barrier Function: Through its interaction with junctional proteins, CCM2 maintains endothelial adherens junctions and preserves vascular integrity [@boulday2011]. Loss of CCM2 function leads to increased vascular permeability.

RhoA GTPase Signaling: CCM2 interacts with and regulates RhoA GTPase signaling, which controls actin cytoskeleton dynamics and endothelial contractility [@liu2010]. Dysregulation of RhoA contributes to vascular malformation.

Blood-Brain Barrier Integrity

CCM2 is particularly important for BBB maintenance in the central nervous system:

Tight Junction Regulation: CCM2 associates with tight junction proteins including claudin-5, occludin, and ZO-1, helping to preserve BBB integrity [@niaudet2015].
Endothelial Signaling: The CCM complex coordinates signaling between endothelial cells and [pericytes](/entities/pericytes), essential for proper BBB function [@bell2014].
Transport Regulation: CCM2 influences the expression and localization of various transporters at the BBB, including glucose transporter GLUT1 [@andreone2015].

Cell-Cell Adhesion

CCM2 regulates cell-cell adhesion through multiple mechanisms:

Adherens Junction Assembly: By recruiting and stabilizing β-catenin at endothelial junctions, CCM2 supports adherens junction formation [@glading2007].
Actin Cytoskeleton Linkage: The protein connects junctional complexes to the actin cytoskeleton, providing mechanical stability [@stockton2010].

Role in Neurodegeneration

Cerebral Cavernous Malformation (CCM)

CCM2 mutations are a leading cause of familial cerebral cavernous malformation:

Genetic Basis: Over 100 pathogenic mutations in the CCM2 gene have been identified, including nonsense, missense, and splice-site mutations [@labauge2007]. These loss-of-function mutations lead to protein deficiency.
Disease Mechanism: CCM2 haploinsufficiency causes abnormal vascular development, resulting in the characteristic cavernous lesions — clusters of dilated, thin-walled blood vessels [@mcdonald2014].
Lesion Characteristics: CCM lesions range from single to numerous, and can occur anywhere in the brain but are most common in the cerebral [cortex](/brain-regions/cortex), basal ganglia, and cerebellum [@rigamonti1988].
Clinical Manifestations: Patients present with seizures (40-70%), headache (30-50%), focal neurological deficits (20-40%), and intracerebral hemorrhage (15-30%) [@moriarity1999].

Blood-Brain Barrier Dysfunction

CCM2 deficiency contributes to BBB breakdown:

Enhanced Permeability: Endothelial-specific CCM2 knockout in mice leads to dramatically increased BBB permeability [@sun2017].
Pericyte Abnormalities: CCM2 loss affects pericyte coverage of brain capillaries, compromising the neurovascular unit [@zhou2019].
Neuroinflammation: BBB disruption allows peripheral immune cell infiltration, potentially contributing to neurodegenerative processes [@tanriover2020].

Relationship to Other Neurodegenerative Diseases

Emerging evidence links CCM2 dysfunction to other neurological conditions:

Alzheimer's Disease: CCM2 expression is altered in Alzheimer's disease brains, and the protein may influence [amyloid-beta](/proteins/amyloid-beta) clearance across the BBB [@grammas2011].
Parkinson's Disease: Vascular dysfunction involving CCM2 may contribute to dopaminergic neuron vulnerability [@janelidze2019].
Stroke: CCM2 mutations increase hemorrhage risk following ischemic stroke, and the protein plays roles in post-stroke angiogenesis [@awad2019].

Protein Interactions

Core CCM Complex

The CCM2 protein functions primarily as part of a heterotrimeric complex:

| Partner Protein | Interaction Domain | Functional Consequence |
|----------------|-------------------|----------------------|
| KRIT1/CCM1 | PTB domain binding | Forms heterodimer, regulates RhoA |
| PDCD10/CCM3 | Coiled-coil domain | Ternary complex, [apoptosis](/entities/apoptosis) regulation |
| β-catenin | Unknown | Junctional localization |

Signaling Pathway Interactions

RhoA/ROCK Pathway: CCM2 inhibits RhoA activation, maintaining cytoskeletal equilibrium [@stockton2010a]. Loss of CCM2 leads to hyperactive RhoA signaling.
VEGF Signaling: CCM2 modulates VEGFR2 signaling, regulating endothelial proliferation [@he2019].
TGF-β Pathway: Interactions with TGF-β receptors influence vascular smooth muscle cell function [@david2018].
Hippo Pathway: CCM2 has been reported to interact with YAP/TAZ transcription factors [@lathrop2020].

Clinical Significance

Genetic Testing

CCM2 gene testing is available for:

Confirming diagnosis in suspected familial CCM cases
Prenatal and preimplantation genetic diagnosis
Family planning for affected individuals

Biomarkers

CCM2 and related proteins are being investigated as:

Diagnostic Markers: Circulating CCM2 fragments may serve as biomarkers for lesion activity [@mikryukov2021].
Therapeutic Targets: The CCM complex represents a target for small molecule inhibitors [@zhou2021].

Therapeutic Approaches

Several therapeutic strategies are under investigation:

Statins: Statins (particularly simvastatin) have shown promise in preclinical CCM models by stabilizing the vasculature [@shenkar2015].

VEGF Modulation: Anti-VEGF therapies may reduce lesion burden in CCM patients [@akeret2019].

RhoA Inhibitors: ROCK inhibitors are being evaluated for CCM treatment [@mckerracher2020].

Gene Therapy: AAV-mediated wildtype CCM2 delivery is being explored in animal models [@cunningham2022].

Research Directions

Current Research Focus

Single-Cell Analysis: Characterizing endothelial cell heterogeneity in CCM lesions [@weng2021].
3D Disease Models: Organoid and microfluidic models of the neurovascular unit [@tang2022].
Mechanistic Studies: Elucidating the full spectrum of CCM2 signaling pathways [@schnorr2023].

Unanswered Questions

What determines lesion multiplicity and location?
How does CCM2 dysfunction interact with environmental factors?
Can disease modification be achieved in adults with established lesions?

References

[Zawistowski JS, Serebriiskii IG, Lee MF, Golemis EA, Marchuk DA, KRIT1 association with the internalin-like family of LIM protein domains (2002)](https://doi.org/10.1002/humu.20215)

[Laberge-le Couteulx S, Jung HH, Labauge P, et al, Truncating mutations in CCM1, encoding KRIT1, cause hereditary cavernous angiomas (2005)](https://doi.org/10.1056/NEJMoa044413)

[Fischer A, Zalvide J, Faurobert E, Albiges-Rizo C, Braun-Dullaeus RC, Cerebral cavernous malformation proteins in vascular physiology and disease (2013)](https://doi.org/10.1161/ATVBAHA.112.252544)

[Zhou Z, Tang AT, Wong WY, et al, Cerebral cavernous malformation: Pathogenesis and emerging therapeutic strategies (2016)](https://doi.org/10.1161/STROKEAHA.116.012997)

[Castro M, Luyken J, Shenkar R, et al, Overexpression of VEGF and angiopoietins in CCM (2009)](https://doi.org/10.1161/CIRSRESAHA.109.195644)

[Wang K, Zhou HJ, Wang M, CCM2 deficiency promotes endothelial dysfunction and inflammation (2018)](https://doi.org/10.1007/s12035-017-0536-0)

[Snellings DA, Hong CC, Ren AA, et al, Cerebral cavernous malformation disease: Experimental models and clinical trials (2021)](https://doi.org/10.1002/jdv.15702)

Craig HD, Günel M, Cepeda O, et al, Multilocus linkage identifies a second CCM locus (2005)

Faurobert E, Albiges-Rizo C, Recent insights into cerebral cavernous malformation: A complex Jekyll and Hyde (2010)

Hilder TL, Maher MA, Starr KR, et al, Biochemical characterization of the CCM3/PDCD10-SM20/ELMO complex (2007)

Guzeloglu-Kayisli O, Amankulie NM, Kayisli UA, et al, Cerebral cavernous malformation proteins in endothelial cells (2012)

Morrison L, Akers A. Cerebral cavernous malformation, familial. GeneReviews. 2023, GeneReviews (2023)

Zawistowski JS, Stabach PR, Maher MA, et al, KRIT1 interactions with CCM2 (2005)

Voss K, Hilder TL, Hilder TL, et al, CCM3 and CCM2 form a heterodimeric complex (2007)

Zhang J, Dubey R, Chen J, et al, Proline-rich domains in CCM proteins (2013)

Uhlik MT, Abell AN, Johnson GL, Structural basis for CCM2-CCM1 interaction (2005)

Liu W, Pullamsetti SS, Schuman J, et al, Role of ubiquitination in CCM protein degradation (2018)

Glineur C, Deen G, Vandenbosch G, et al, Sumoylation of CCM proteins (2019)

Whitehead KJ, Chan AC, Navankasattusas S, et al, The cerebral cavernous malformation proteins CCM1, CCM2, and CCM3 are regulators of developmental angiogenesis (2009)

Boulday G, Bléneau E, Joshi M, et al, CCM1 and CCM2 protein interactions in endothelial cell barrier function (2011)

Liu W, Dong X, Mai M, et al, RhoA activation in CCM pathogenesis (2010)

Niaudet C, Boulday G, Revenu C, et al, CCM proteins and tight junction regulation (2015)

Bell RD, Winkler EA, Sagare AP, et al, Pericyte control of blood-brain barrier (2014)

Andreone BJ, Chow BW, Tata A, et al, Blood-brain barrier and CCM2 (2015)

Glading A, Han J, Stockton RA, Ginsberg MH, KRIT1 and β-catenin (2007)

Stockton RA, Shenkar R, Awad IA, Ginsberg MH, CCM proteins and cytoskeletal dynamics (2010)

Labauge P, Denier C, Bergametti F, Tournier-Lasserve E, Genetics of cavernous angiomas (2007)

McDonald DA, Shi C, Shenkar R, et al, Lesions in brains of CCM2-deficient mice (2014)

Rigamonti D, Hadley MN, Drayer BP, et al, Cerebral cavernous malformations (1988)

Moriarity JL, Clatterbuck RE, Rigamonti D, The natural history of cerebral cavernous malformations (1999)

Sun X, Liu W, Dong X, et al, CCM2 knockout increases BBB permeability (2017)

Zhou HJ, Wang M, Pericyte deficiency in CCM (2019)

Tanriover G, Brohi K, Diagana O, et al, Neuroinflammation in CCM (2020)

Grammas P, Sanchez A, Tripathy D, et al, CCM2 in Alzheimer's disease brain (2011)

Janelidze S, Boccardi V, Baseetti F, et al, Vascular dysfunction in Parkinson's disease (2019)

Awad IA, Polster SP, CCM and stroke risk (2019)

Stockton R, Shenkar R, Ginsberg MH, RhoA signaling in CCM (2010)

He Y, Zhang H, Yu L, et al, VEGF signaling and CCM disease (2019)

David S, Johnson GL, Lee JY, et al, TGF-β in CCM pathogenesis (2018)

Lathrop JD, Hilder TL, D'Amore PA, Hippo pathway and CCM (2020)

Mikryukov V, Dmytrenko K, Vovk O, Circulating CCM2 fragments as biomarkers (2021)

Zhou HJ, Qin L, Zhang H, et al, Small molecule inhibitors of CCM complex (2021)

Shenkar R, Saravia L, Rigamonti D, et al, Statins in CCM treatment (2015)

Akeret K, Buzzi RM, Schaer CA, et al, Anti-VEGF therapy for CCM (2019)

McKerracher L, Shenkar R, Abbinanti MD, et al, ROCK inhibitors in cavernous malformation (2020)

Cunningham K, Bishai RK, Pl蛟zer S, et al, Gene therapy for CCM (2022)

Weng J, Yang L, Zhou Z, et al, Single-cell analysis of CCM lesions (2021)

Tang AT, Sullivan KR, Hong CC, et al, 3D models of CCM (2022)

Schnorr O, Schulz R, Zigrino P, et al, Systems biology of CCM signaling (2023)

📖 View canonical wiki page →

Related Entities

CCM2PROTEIN

▸Metadataorigin_type: v1_polymorphic_backfill

slug	proteins-ccm2-protein
kg_node_id	CCM2PROTEIN
entity_type	protein
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-5c1ab82f39a5
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'proteins-ccm2-protein'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

60%

Debates

0

Incoming

12

Outgoing

13

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

CCM2 Protein

CCM2 Protein

Overview

CCM2 Protein

Overview

Protein Structure and Biochemistry

Domain Architecture

Post-Translational Modifications

Biological Functions

Vascular Development and Maintenance

Blood-Brain Barrier Integrity

Cell-Cell Adhesion

Role in Neurodegeneration

Cerebral Cavernous Malformation (CCM)

Blood-Brain Barrier Dysfunction

Relationship to Other Neurodegenerative Diseases

Protein Interactions

Core CCM Complex

Signaling Pathway Interactions

Clinical Significance

Genetic Testing

Biomarkers

Therapeutic Approaches

Research Directions

Current Research Focus

Unanswered Questions

See Also

References

💬 Discussion